Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs061230048
JPRN-jRCTs061230048
Recruiting
Phase 3

A Phase III Trial of the Efficacy and Safty of the Probiotics for the Prevention of Postoperative Infections after Lung Resection

Hamano Kimikazu0 sites700 target enrollmentAugust 16, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Hamano Kimikazu
Enrollment
700
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 16, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hamano Kimikazu

Eligibility Criteria

Inclusion Criteria

  • •(1\) Outpatients or hospitalized patients scheduled for thoracoscopic anatomical lung resection (lobectomy or segmentectomy) for pulmonary lesions
  • •(2\) Patients suspected of primary lung cancer by CT or PET\-CT, or diagnosed with primary lung cancer by bronchoscopy or CT\-guided biopsy
  • •(3\) Patients aged 20 years or older at the time of informed consent
  • •(4\) Patients who have given written informed consent of their own free will after receiving sufficient explanation about participating in this study

Exclusion Criteria

  • •(1\) Patients with a history of allergy to probiotics
  • •(2\) Patients with a history of side effects due to oral administration of probiotics
  • •(3\) Patients who have already received continuous administration of probiotics
  • •(4\) Patients who are currently taking probiotics regularly as guidance\-required or over\-the\-counter drugs
  • •(5\) Patients undergoing treatment for any infectious disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, ßS/ßC GenotypeSickle cell anaemiaMedDRA version: 21.0Level: PTClassification code: 10040641Term: Sickle cell anaemia Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
CTIS2023-503247-34-00Vertex Pharmaceuticals Inc.14
Not yet recruiting
Phase 3
ow dose gemcitabine vs standard dose gemcitabine in advanced lung cancerHealth Condition 1: null- Advanced non-small cell lung cancer
CTRI/2013/02/003422Tata Memorial Hospital308
Active, not recruiting
Phase 1
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBVChronic Hepatitis C Virus Infection (Genotype 1, 2, 3, 4)MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2012-003463-22-FRBristol-Myers Squibb International Corporation71
Active, not recruiting
Phase 3
A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgarisAcne vulgarisSkin and Connective Tissue Diseases
ISRCTN18067422PPM Services S.A400
Active, not recruiting
Phase 3
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in subjects with Transfusion-Dependent β-Thalassemia
2024-516894-57-00Vertex Pharmaceuticals Inc.5